What is it about?
Human dihydroorotate dehydrogenase is a validated therapeutic target for the treatment of autoimmune diseases, however human DHODH inhibitors have also been investigated as treatment for cancer, parasite infections (i.e. malaria) and viruses. This review focuses on recent advances in the development and application of hDHODH inhibitors, specifically covering the patent field.
Featured Image
Why is it important?
The most important and well-described novelty is the discovery that hDHODH inhibitors are able to induce in vivo myeloid differentiation has led to the possibility of developing novel hDHODH based treatments for Acute Myelogenous Leukemia (AML).
Perspectives
It is possible developing novel hDHODH to treat Acute Myelogenous Leukemia (AML).
Donatella Boschi
Universita degli Studi di Torino
Read the Original
This page is a summary of: Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy, Recent Patents on Anti-Cancer Drug Discovery, January 2018, Bentham Science Publishers,
DOI: 10.2174/1574892812666171108124218.
You can read the full text:
Contributors
The following have contributed to this page
